Abstract
Rationale
d-Cycloserine, a partial agonist at the glycine site of the N-methyl-d-aspartate receptor, has demonstrated inconsistent efficacy for negative and cognitive symptoms of schizophrenia. The strongest evidence for efficacy has come from studies using d-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less.
Objective
To assess the efficacy for negative symptoms and cognitive impairment of d-cycloserine augmentation of conventional antipsychotics in a 6-month trial.
Methods
Fifty-five schizophrenia patients with prominent negative symptoms, treated with conventional antipsychotics, were randomly assigned to treatment with d-cycloserine 50 mg/day or placebo for 6 months in a double-blind, parallel group design.
Results
Twenty-six subjects completed the 6-month trial; drop-out rates did not differ between treatment groups. d-Cycloserine treatment did not differ from placebo treatment on any primary outcome measure at 8 or 24 weeks, including response of negative symptoms and performance on a cognitive battery. Serum d-cycloserine concentrations did not correlate with response of negative symptoms.
Conclusion
d-Cycloserine did not exhibit therapeutic effects in this trial, possibly reflecting the high drop-out rate, a narrow range of therapeutic serum concentrations, a modest magnitude of therapeutic effect for the selected outcome measures, or loss of efficacy over time. Because d-cycloserine is a partial agonist with relatively low affinity for the glycine site, the magnitude of potential therapeutic effect may be smaller than that achieved by the higher-affinity full agonists, glycine and d-serine.
Similar content being viewed by others
References
Andreasen N (1984) Modified scale for the assessment of negative symptoms. National Institutes of Mental Health publication ADEM 9–102
van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS (1996) Efficacy and tolerance of d-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 40:1298–1300
van Berckel BNM, Evenblij CN, van Loon BJAM, Maas MF, van der Geld MAM, Wynne HJ, van Ree JM, Kahn RS (1999) d-Cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21:203–210
Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994) d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm [Gen Sect] 95:105–111
Chessell I, Procter A, Francis P, Bowen D (1991) d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 565:345–348
Crane GE (1959) Cycloserine as an antidepressant agent. Am J Psychiatry 115:1025–1026
Danysz W, Parsons C (1998) glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597–664
D’Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH (2000) IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 47:450–462
Evins A, Fitzgerald S, Wine L, Roselli R, Goff D (2000) A placebo controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826–828
Ganote C, Peterson D, Carone F (1974) The nature of d-serine-induced nephrotoxicity. Am J Pathol 77:269–282
Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377
Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213–1215
Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996) d-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628–1630
Goff D, Henderson D, Evins A, Amico E (1999a) A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45:512–514
Goff D, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld D, Hayden D, McCarley R, Coyle J (1999b) A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21–27
Guy W (1976) ECDEU Assessment manual for psychopharmacology. US Department of Health, Education, and Welfare
Hamilton MA (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Heinrichs DW, Hanlon TE, Carpenter WT (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388–396
Henderson G, Johnson JW, Ascher P (1990) Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-d-aspartate receptor. J Physiol 430:189–212
Heresco-Levy U, Javitt D (2004) Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66:89–96
Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617
Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J (1998) Double-blind, placebo-controlled, crossover trial of d-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 3:131–135
Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, Lichenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29–36
Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002) Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480–482
Javitt DC, Zylberman I, Zukin SR, Heresco LU, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234–1236
Jones LR (1956) Colorimetric determination of cycloserine, a new antibiotic. Anal Chem 28:39–41
Jones BN (1986) Amino acids by ophthaldialdehyde precolumn derivatization and reverse-phase HPLC. In: Shively JE (ed) Method of protein microcharacterization. Humana, Clifton, pp 121–151
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
Kendig IV, Charen S, Lepine LT (1956) Psychological side-effects induced by cycloserine in the treatment of pulmonary tuberculosis. Am Rev Tuberc 73:438–441
Kirkpatrick B, Buchanan R, McKenney P (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119–123
Luborsky L (1962) Clinicians’ judgments of mental health. Arch Gen Psychiatry 7:407–417
Potkin S, Jin Y, Bunney B, Costa J, Gulasekaram B (1999) Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156:145–147
Simeon J, Fink M, Itil T, Ponce D (1970) d-Cycloserine therapy of psychosis by symptom provocation. Comp Psychiatry 11:80–88
Simpson GM, Angus JWS (1970) Drug-induced extrapyramidal disorders. Acta Psychiatr Scand Suppl 212:11–19
Tsai G, Yang P, Chung L-C, Lange N, Coyle J (1998) d-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081–1089
Tsai G, Yang P, Chung L-C, Tsai I-C, Tsai C-W, Coyle J (1999) d-Serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156:1822–1825
Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990) d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510:158–160
Acknowledgements
This study was supported by PHS RO1 MH54245, K24 MH02025, and P50 MH60450.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goff, D.C., Herz, L., Posever, T. et al. A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 179, 144–150 (2005). https://doi.org/10.1007/s00213-004-2032-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-004-2032-2